In rare diseases such as Duchenne, where the disease population is small, the drug development process can vary from that of more common diseases, and totally new treatment approaches such […]
NEWPORT BEACH, Calif. (September 10, 2019) – Finding the right mobility equipment for Duchenne muscular dystrophy patients can be a time intensive and frustrating process. To help take the guesswork […]
View the Sarepta Summer 2019 Newsletter HERE.
The nonprofit CureDuchenne has chosen veteran advocacy leader Erin Frey to become its first director of Duchenne muscular dystrophy (DMD) advancement efforts. Read the full article HERE.
NEWPORT BEACH, Calif. (August 26, 2019) – Receiving a positive diagnosis for Duchenne muscular dystrophy is devastating for new parents. Likewise, learning about the rare disease and how to care […]
Today’s FDA disapproval of Sarepta’s Vyondys 53 is disheartening, but a true example of just how difficult and costly the drug development process is. We appreciate Sarepta’s efforts and dedication […]
The latest edition of the Catabasis Connection newsletter discusses Phase 3 PolarisDMD trial for edasalonexent in Duchenne. Read the full newsletter here.
Organizations to provide financial support for 50 Duchenne families to travel to Southern California for the CureDuchenne 2019 FUTURES national conference NEWPORT BEACH, Calif. (July 1, 2019) — CureDuchenne, the […]
Pfizer made their first public disclosure on early data from their open-label Phase 1 microdystrophin gene therapy trial for the treatment of Duchenne. The program was obtained from Pfizer’s acquisition […]
